Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
5 pending office actions • 2 art units • 5 examiners • 0 of 5 (0%) have an AI response strategy ready • 5 patents granted in the last 365 days
Bioverativ Therapeutics Inc. has 4 pending office actions focused in the Biotechnology & Pharmaceuticals technology area. These actions are assigned to 4 distinct examiners, which indicates that the company's current prosecution workload is spread across several different individuals. The data also shows 2 distinct art units, suggesting that the 4 pending office actions are being evaluated by two different technical groups within the Biotechnology & Pharmaceuticals field.
The busiest examiner identified is CHORBAJI, MONZER R, who handles 1 busiest examiner pending office action. This 1 action is part of the 4 pending office actions currently active in the portfolio. With 4 distinct examiners and 2 distinct art units involved, the company's prosecution strategy must account for the specific requirements of each individual examiner. Successfully resolving the 4 pending office actions will require a tailored approach for each of the 4 distinct examiners while managing the standards of the 2 distinct art units.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (20%) |
| Double-patenting + other | 2 (40%) |
| Multi-statute (no §101) | 2 (40%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CHORBAJI, MONZER R | 1 | 76.4% | +21.3% |
| SABILA, MERCY HELLEN | 1 | 57.0% | +46.4% |
| YU, DELPHINUS DOU YI | 1 | 33.3% | +0.0% |
| JACKSON III, WALTER | 1 | 100.0% | +0.0% |
| LIPPOLIS, ALEXANDRA ROSE | 1 | 46.9% | +59.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18440711 | BACULOVIRUS EXPRESSION SYSTEM | JACKSON III, WALTER | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18903305 | ON-COLUMN VIRAL INACTIVATION METHODS | CHORBAJI, MONZER R | — |
| 18617239 | NUCLEIC ACIDS ENCODING FACTOR VIII POLYPEPTIDES WITH REDUCED IMMUNOGENICITY | YU, DELPHINUS DOU YI | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17576561 | BACULOVIRUS EXPRESSION SYSTEM | LIPPOLIS, ALEXANDRA ROSE | 52d overdue |
| 18903305 | ON-COLUMN VIRAL INACTIVATION METHODS | CHORBAJI, MONZER R | — |
| 18656168 | METHODS OF TREATING HEMOPHILIA A | SABILA, MERCY HELLEN | — |
| Art Unit | Apps |
|---|---|
| 1638 | 1 |
| 1637 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18903305 | ON-COLUMN VIRAL INACTIVATION METHODS | CHORBAJI, MONZER R | — | §102§103 | Non-Final OA | — | Pending | Oct 01, 2024 |
| 18656168 | METHODS OF TREATING HEMOPHILIA A | SABILA, MERCY HELLEN | — | §102§103DP | Non-Final OA | — | Pending | May 06, 2024 |
| 18617239 | NUCLEIC ACIDS ENCODING FACTOR VIII POLYPEPTIDES WITH REDUCED IMMUNOGENICITY | YU, DELPHINUS DOU YI | — | §102§103§112 | Non-Final OA | — | Pending | Mar 26, 2024 |
| 18440711 | BACULOVIRUS EXPRESSION SYSTEM | JACKSON III, WALTER | 1638 | §103 | Non-Final OA | — | Pending | Feb 13, 2024 |
| 17576561 | BACULOVIRUS EXPRESSION SYSTEM | LIPPOLIS, ALEXANDRA ROSE | 1637 | §103DP | Non-Final OA | 52d overdue | Pending | Jan 14, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial